peptuity.
WhatsApp

Head to head

Semaglutide vs Tirzepatide

Two compounds, one grading system.

Same evidence tier — but Semaglutide carries more randomised trials (640 vs 210).

01

At a glance

SemaglutideFDA approved

GLP-1 agonist. Approved, trial-backed, and genuinely effective for weight and glycaemic control.

17,774publications
640RCTs
TirzepatideFDA approved

Dual GIP/GLP-1 agonist. Approved, and outperformed semaglutide in head-to-head trials.

7,505publications
210RCTs
02

Side by side

Attribute Semaglutide Tirzepatide
GoalMetabolic & fat lossMetabolic & fat loss
EvidenceFDA approvedFDA approved
Publications17,7747,505
Randomised trials640210
Sport (WADA)not listednot listed
US compounding——
03

Claims vs data

Semaglutide — claims vs data

Produces clinically meaningful weight losssupported
Improves glycaemic control in type 2 diabetessupported
Free of side effectsoverreach

Tirzepatide — claims vs data

Greater average weight loss than semaglutidesupported
Requires no medical supervisionoverreach
Full Semaglutide profile Full Tirzepatide profile All comparisons
Research use only

All content on Peptuity is provided for research and educational purposes only. Peptuity does not sell, distribute, or facilitate the purchase of any compound, does not provide medical advice, and makes no claims regarding safety or efficacy. Most compounds discussed are not approved for human use by the SFDA or FDA. Always consult a qualified physician.

Ask a question